Illumina (ILMN)
Life-science tools and diagnostics
Close on Nov 11, 2026 (from our latest Long View update): $212.93
- Market value
- $32.2Bat the Nov 11 close
- Revenue growth
- +6%12 months to Sep 27, 2026 (10-Q)
- FCF margin
- 23%12 months to Sep 27, 2026 (10-Q)
- Net debt
- $454Mat Sep 27, 2026
- Worst fall since listing
- −96.1%Sep 1, 2000 to Mar 13, 2003; back to that high in Jul 2007
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
Illumina’s 2021 purchase of GRAIL, closed while European regulators were still reviewing it, led to a prohibition, a fine, about $6.6B of write-downs and a change of chief executive before GRAIL was spun off in 2024.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 12, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names Illumina
Long-term fundamentals
Annual results for Illumina, FY2009–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $666M in FY2009 to $4.3B in FY2025.
Free cash flow was positive in 17 of the 17 years shown; FY2025: $931M.
Margins
Operating margin was 19% in FY2025, vs 18% in FY2020.
Gross margin was 66% in FY2025, vs 68% in FY2020.
Diluted share count
The diluted share count rose 5% from FY2020 to FY2025, to 156M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $4.3B | 66% | 19% | $850M | $1.1B | $148M | $931M |
| FY2024 | $4.4B | 65% | −19% | −$1.2B | $837M | $128M | $709M |
| FY2023 | $4.5B | 61% | −24% | −$1.2B | $478M | $195M | $283M |
| FY2022 | $4.6B | 65% | −91% | −$4.4B | $392M | $286M | $106M |
| FY2021 | $4.5B | 70% | −3% | $762M | $545M | $208M | $337M |
| FY2020 | $3.2B | 68% | 18% | $656M | $1.1B | $189M | $891M |
| FY2019 | $3.5B | 70% | 28% | $1.0B | $1.1B | $209M | $842M |
| FY2018 | $3.3B | 69% | 26% | $826M | $1.1B | $296M | $846M |
| FY2017 | $2.8B | 66% | 22% | $726M | $875M | $310M | $565M |
| FY2016 | $2.4B | 69% | 24% | $463M | $779M | $260M | $519M |
| FY2015 | $2.2B | 70% | 28% | $462M | $786M | $143M | $643M |
| FY2014 | $1.9B | 70% | 28% | $353M | $501M | $106M | $395M |
| FY2013 | $1.4B | 64% | 9% | $125M | $386M | $79M | $307M |
| FY2012 | $1.1B | 67% | 17% | $151M | $292M | $69M | $223M |
| FY2011 | $1.1B | 67% | 19% | $87M | $358M | $78M | $280M |
| FY2010 | $903M | 67% | 23% | $125M | $273M | $50M | $223M |
| FY2009 | $666M | 68% | 19% | $72M | $172M | $53M | $120M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 156M | $1.4B | $2.0B | $275M | — | $742M |
| FY2024 | 159M | $1.1B | $2.0B | $370M | — | $116M |
| FY2023 | 158M | $1.0B | $1.5B | $380M | — | $0 |
| FY2022 | 157M | $2.0B | $2.7B | $366M | — | $0 |
| FY2021 | 151M | $1.2B | $1.7B | $754M | — | $0 |
| FY2020 | 148M | $3.1B | $1.2B | $194M | — | $736M |
| FY2019 | 149M | $3.3B | $1.1B | $194M | — | $324M |
| FY2018 | 149M | $3.5B | $2.0B | $193M | — | $201M |
| FY2017 | 148M | $2.1B | $1.2B | $164M | — | $251M |
| FY2016 | 148M | $1.6B | $1.1B | $129M | — | $249M |
| FY2015 | 149M | $1.4B | $1.1B | $133M | — | $274M |
| FY2014 | 149M | $1.3B | $1.3B | $153M | — | $237M |
| FY2013 | 140M | $1.2B | $869M | $106M | — | $50M |
| FY2012 | 134M | $1.4B | $805M | $94M | — | $83M |
| FY2011 | 139M | $1.2B | $807M | $92M | — | $570M |
| FY2010 | 143M | $894M | — | $72M | — | $44M |
| FY2009 | 137M | $694M | — | $61M | — | $175M |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 12, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Cash for FY2019-2025 includes restricted cash (the only cash total tagged).
Returns by year
| Year | ILMN | S&P 500 |
|---|---|---|
| 2019 | +10.6% | +31.5% |
| 2020 | +11.5% | +18.4% |
| 2021 | +2.8% | +28.7% |
| 2022 | −46.9% | −18.1% |
| 2023 | −31.1% | +26.3% |
| 2024 | −1.3% | +25.0% |
| 2025 | −1.8% | +17.9% |
| 2026 to date | +53.0% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- GMAB Genmab Up 28.3%
- ALNY Alnylam
- IDXX IDEXX Laboratories Up 21.8%
- MRNA Moderna Down 17.6%
- MDGL Madrigal Down 8.1%
- TGTX TG Therapeutics Up 5.9%
Show all 26
- CORT Corcept Therapeutics Down 20.1%
- KRYS Krystal Down 11%
- IBRX ImmunityBio Down 17.7%
- ARWR Arrowhead Down 15.3%
- HIMS Hims & Hers Down 16.6%
- IOVA Iovance Down 35.4%
- LEGN Legend Down 16%
- TNGX Tango Therapeutics Down 16.4%
- SLS SELLAS Up 156.4%
- IRTC iRhythm Down 30.7%
- VKTX Viking Therapeutics
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- VCYT Veracyte Down 54.3%
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- WGS GeneDx Up 4428%
- IMCR Immunocore Up 9.1%
- ORIC ORIC Pharmaceuticals Down 32%
- PACB PacBio Down 11.4%
Questions about Illumina
- Why did Illumina stock fall on Oct 30, 2026?
- Illumina shares fell about 19% on Friday, after the drop began after hours on Thursday, despite an earnings beat and higher full-year forecasts. StockStory called revenue a miss, but Illumina's $37 million reduction for expected customer tariff credits complicates that comparison. The reporting so far does not establish what drove the selling. Read the article →